Burssens A, Thiery J, Kohl P, Molderez A, Haazen L
Physical Medicine and Rehabilitation Unit, St. Barbara University Hospital, Pellenberg, Belgium.
Acta Orthop Belg. 1995;61(3):205-11.
The effect of tenoxicam 10 mg and 20 mg, administered daily for 6 weeks to prevent heterotopic bone formation after total hip arthroplasty, was evaluated in a randomized, double-blind, placebo-controlled trial involving 90 patients. After 3 months, patients who had received the active drug, including those who had received only half the recommended anti-inflammatory dosage, had significantly less heterotopic bone formation. After 6 months the difference between treatment groups and placebo became smaller but remained significant. Adverse reactions occurred in only 3 patients, reflecting no differences between the groups. The study results, including radiographic, clinical and biochemical evaluations, demonstrate that treatment with tenoxicam 20 mg daily and even with tenoxicam 10 mg daily for 6 weeks, starting immediately after total hip arthroplasty, is effective in preventing ectopic bone formation.
在一项涉及90名患者的随机、双盲、安慰剂对照试验中，评估了每天服用10毫克和20毫克替诺昔康，持续6周以预防全髋关节置换术后异位骨形成的效果。3个月后，接受活性药物治疗的患者，包括那些仅接受推荐抗炎剂量一半的患者，异位骨形成明显较少。6个月后，治疗组与安慰剂组之间的差异变小，但仍具有统计学意义。仅3名患者出现不良反应，表明各组之间无差异。该研究结果，包括影像学、临床和生化评估，表明全髋关节置换术后立即开始，每天服用20毫克替诺昔康，甚至每天服用10毫克替诺昔康，持续6周，可有效预防异位骨形成。
